Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes typeThe invention relates to medicaments containing at least one GC-C agonist.URS EGNERMARKUS MEYERWOLF-GEORG FORSSMANN
USE OF GUANYLATE CYCLASE-C (GC-C) AGONISTS AS INSULINOTROPIC FACTORS FOR TREATING DIABETES TYPE 2The invention relates to medicaments containing at least one guanylate cyclase-C agonist for treating diabetes mellitus type 2.doi:WO2001080871 A2Urs Egner...
Differential effects of extracellular cyclic GMP (cGMP) and the guanylate cyclase-C (GC-C) agonist, linaclotide, on mouse gastric vagal afferent mechanosen... Brierley,M S.,Kurtz,... - 《Neurogastroenterology & Motility》 被引量: 0发表: 2014年 Structure and function of the heat-stable ...
956 IW-9179, a Potent Guanylate Cyclase-C (GC-C) Agonist, Improves Gastric Emptying In Vivo and Modulates Gastric Vagal Afferent Mechanosensitivity In Vitro956 IW-9179, a Potent Guanylate Cyclase-C (GC-C) Agonist, Improves Gastric Emptying In Vivo and Modulates Gastric Vagal Afferent Mechanosens...
Finally, the role of GC-C in chloride secretion can be exploited in the treatment of constipation as suggested by a recent study on linaclotide, a GC-C agonist (35). Our finding of a polar response to GC-C provides a novel view of the role of GC-C. The differential response to ...
TGR5 agonist inhibits intestinal epithelial cell apoptosis via cAMP/PKA/c-FLIP/JNK signaling pathway and ameliorates dextran sulfate sodium-induced ulcerative ... WJ Yang,F Han,YP Gu,... - 《Acta Pharmacologica Sinica》 被引量: 0发表: 2023年 Tu1229 The Effects of a TGR5 Agonist and a Dipep...
法洛芬 是GABA | B |受体的选择性拮抗剂。法洛芬 是GABA激动剂巴氯酚的膦酸衍生物,并被描述为竞争性拮抗对外源施用的巴氯酚的响应。 Phaclofen is a selective antagonist of the GABA|B|receptor. Phaclofen is a phosphonic acid derivative of the GABA|B|agonist Baclofen , and is described to competiti...
OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in ty... B Zinman,J Gerich,JB Buse,... - 《Diabetes Care》 被引量: 1738发表: 2009年 Management of hyperglycaemia in type 2 diabetes, 2015...
The present invention relates to a process for the preparation of Linaclotide by coupling of two or three suitable fragments by solid phase synthesis.GOUD Agasaladinni NAGANAKUMAR Vadlamani SURESHAuro Peptides Ltd. (2015). A Process for the Preparation of GC-C Agonist. WO022575 (A3). ...
A PROCESS FOR THE PREPARATION OF GC-C AGONISTThe present invention relates to a process for the preparation of Linaclotide of formula I, H-Cys Cys-Glu-Tyr Cys Cys- Asn- Pro- Ala Cys Thr-Gly-Cys Tyr-OH Formula I b J; 1 5 S I S S by coupling of two or three fragments by solid...